Developing an ATMP to Boost Post-Transplant Immune Protection in Pediatric Leukemia and Neuroblastoma
Morandi F, Lastra MD, Airoldi I, et al. A Novel GMP-Manufactured Medicinal Product Candidate Composed of NK and γδ T Cells as Adjunct Immunotherapy for Hematopoietic Stem Cell Transplantation. Cell Transplantation. 2026; (doi: 10.1177/09636897251374248)
Scientists have developed an advanced therapy medicinal product (ATMP) that aims to protect leukemia patients against tumor relapse and potentially fatal infection following haploidentical hematopoietic stem cell transplantation (HSCT). The foundation of the adjunct immunotherapy is pure, activated γδ T lymphocytes and natural killer cells that are cytotoxic to leukemia and neuroblastoma (NB). The infusion, called GADEKILL, is virtually free of αß T lymphocytes and B cells, making it viable for clinical use, especially in the setting of haploidentical HSCT. Other traits include robust homogeneity, cell viability, cytotoxic properties, and stability after cryogenic preservation. Administered in the post-transplant phase, developers envision GADEKILL as an immunological support to guard against tumor relapse and serious infections in children with NB and leukemia.